Our clear purpose is to develop medicines that improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives.
Our achievements would not be possible without the outstanding team that make up Shield Therapeutics’ staff, Senior Executive Team and Board of Directors.
Our Culture & Values
Our focus is our people, patients, partnerships and medicines to create a working culture founded on our core value.
Our lead product is approved for the treatment of iron deficiency with or without anemia in adults in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid 2030s.
Delivering innovative specialty pharmaceuticals to address significant unmet needs in the treatment of iron deficiency.
ACCRUFeR® is a stable, non-salt based oral therapy for adults with iron deficiency with or without anemia.
Shield and our collaborators actively publish and present new data. Please find key publications and posters below.
Shield Therapeutics is a patient-focused, commercial stage pharmaceutical company on a mission to improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives.
Patients & HCPs
Existing treatment options have significant drawbacks and many Health Care Professionals (HCPs) agree there is an unmet need in the market for an effective, convenient and well-tolerated oral iron replacement therapy.
Collaborating and partnering is key to achieving our global success.
Results, Reports & Presentations
Browse our library of results, reports and presentations.
Regulatory Alerts Sign-up
Sign up to Shield Therapeutics plc regulatory news alerts.
Latest regulatory announcements from Shield Therapeutics plc.
We attend a host of investor and scientific events across the world. See details of upcoming events.
Investor News Sign-up
Sign up to investor news alerts
Video & Audio
See video and audio content from Shield Therapeutics
Share Price Center
View our share price information.
As a company whose shares are admitted to trading on AIM, Shield Therapeutics plc is required to comply with the AIM Rules for Companies.
The following analysts currently issue reports on Shield Therapeutics:
Investor & Advisor Contacts
Our investor and advisor contacts should you have a query.
AIM Rule 26
This information on this page is disclosed in accordance with AIM Rule 26.
Welcome to our dedicated investors section.
See latest news from Shield Therapeutics plc
Id volutpat lacus laoreet non leo vel orci porta non pulvinar interdum viverra mauris.
As an ambitious and growing pharmaceutical company we are always looking for new talent to join us. Find out more about life at Shield.
Find out how to get in touch with Shield Therapeutics plc
Shield Therapeutics plc, announces its unaudited interim results for the six months ended 30 June 2021. For further details click here.
Back to News